Diseases / Thrombocytopenia
Thrombocytopenia
DiseaseThrombocytopenia is a condition characterized by a lower-than-normal platelet count, increasing risk of bruising and bleeding. Causes include decreased production, increased destruction, splenic sequestration, medications, infections, and systemic disease.
- Trials
- 406
- Recruiting
- 35
- Completed
- 211
- With results
- 103
Last revised
Pipeline
Phase by status
| Phase | Recruiting | Not yet | By invitation | Active | Completed | Terminated | Withdrawn | Unknown | Available | No longer available | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Early Phase 1 | 1 | 1 | — | — | 2 | — | 2 | — | — | — | 6 |
| Phase 1 | 2 | — | — | — | 20 | 2 | 1 | 1 | — | — | 26 |
| Phase 1/2 | 1 | 1 | — | 1 | 12 | 6 | — | 2 | — | — | 23 |
| Phase 2 | 14 | 3 | — | 1 | 54 | 21 | 6 | 17 | — | — | 116 |
| Phase 2/3 | 1 | 1 | — | 1 | 3 | 3 | — | 6 | — | — | 15 |
| Phase 3 | 2 | 1 | — | — | 33 | 10 | — | 7 | — | — | 53 |
| Phase 4 | 3 | — | — | — | 9 | 5 | 1 | 8 | — | — | 26 |
| Not applicable | 6 | 4 | — | 1 | 19 | 3 | 3 | 3 | — | — | 39 |
| Unknown | 5 | 3 | 2 | 4 | 59 | 4 | 1 | 22 | 1 | 1 | 102 |
Trials started per year
Conditions studied, by phase
| Condition | Early Phase 1 | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | Phase 4 | Not applicable | Unknown | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Thrombocytopenia | 6 | 26 | 23 | 116 | 15 | 53 | 26 | 39 | 102 | 406 |
| Purpura, Thrombocytopenic, Idiopathic | — | 1 | 4 | 10 | — | 24 | 5 | 2 | 5 | 51 |
| Anemia | 1 | 4 | 6 | 12 | 1 | 2 | — | 5 | 8 | 39 |
| Neutropenia | — | 3 | 4 | 12 | — | — | — | 4 | 6 | 29 |
| Hematologic Diseases | — | 2 | — | 6 | 1 | 7 | — | 3 | 7 | 26 |
| Hemorrhage | — | 3 | 1 | 6 | — | 6 | — | — | 10 | 26 |
| Myelodysplastic Syndromes | 1 | 3 | 2 | 11 | 1 | 1 | 1 | 2 | 3 | 25 |
| Anemia, Aplastic | 1 | 1 | 2 | 11 | — | — | — | 1 | 3 | 19 |
| Jacobs syndrome | — | 1 | 2 | 5 | — | 6 | — | 1 | 1 | 16 |
| Autoimmune Diseases | — | 2 | 2 | 8 | — | 1 | — | — | 1 | 14 |
Most active sponsors
| # | Sponsor | Trials | Phase 3 |
|---|---|---|---|
| 1 | GlaxoSmithKline | 20 | 4 |
| 2 | Amgen | 19 | 8 |
| 3 | National Heart, Lung, and Blood Institute (NHLBI) | 14 | 0 |
| 4 | M.D. Anderson Cancer Center | 10 | 3 |
| 5 | Shandong University | 9 | 4 |
| 6 | Novartis Pharmaceuticals | 7 | 2 |
| 7 | Peking University People's Hospital | 6 | 2 |
| 8 | Eisai Inc. | 5 | 2 |
| 9 | Institute of Hematology & Blood Diseases Hospital, China | 5 | 0 |
| 10 | Memorial Sloan Kettering Cancer Center | 5 | 0 |
Most studied interventions
| # | Intervention | Trials |
|---|---|---|
| 1 | eltrombopag | 60 |
| 2 | romiplostim | 34 |
| 3 | avatrombopag | 25 |
| 4 | Platelet Transfusion | 11 |
| 5 | Thrombopoietin | 11 |
| 6 | Blood Specimen Collection | 9 |
| 7 | Cyclosporine | 7 |
| 8 | Rituximab | 7 |
| 9 | Cytarabine | 6 |
| 10 | Dexamethasone | 6 |
Evidence
- Results reported
- 48.8%103 of 211 completed
- Published
- 12.3%26 of 211 completed
- Primary endpoint met
- 53.1%26 of 49 analyses
- Median months to report
- 13.5
Documents disclosed
Trial profile
- Median enrollment
- 60
- Median duration
- 28.6months
- Countries
- 68
- Study sites
- 2879
Who is enrolled
Median enrollment by phase
- Early Phase 1
- 11
- Phase 1
- 25
- Phase 1/2
- 33
- Phase 2
- 35
- Phase 2/3
- 118
- Phase 3
- 130
- Phase 4
- 53
- Not applicable
- 107
- Unknown
- 106
Where trials run
Busiest cities
| # | City | Country | Trials |
|---|---|---|---|
| 1 | New York | United States | 35 |
| 2 | Boston | United States | 34 |
| 3 | Houston | United States | 32 |
| 4 | Los Angeles | United States | 28 |
| 5 | Philadelphia | United States | 25 |
| 6 | Seattle | United States | 25 |
| 7 | Beijing | China | 24 |
| 8 | Bethesda | United States | 24 |
| 9 | Milan | Italy | 22 |
| 10 | Paris | France | 22 |
Terminations
- Terminated
- 54
- Withdrawn
- 14
- Stopped for recruitment
- 7.6%31 of 406 trials
Stated reasons
Reasons are grouped from the sponsor's own wording with a rule-based classifier; the original text is shown below.
Recently stopped
| Trial | Status | Stated reason | Stopped |
|---|---|---|---|
| NCT06291415 Withdrawn | Withdrawn | Sponsor decision | 2026-11-30 |
| NCT07025512 Withdrawn | Withdrawn | PI requested | 2026-05-04 |
| NCT05785819 Terminated | Terminated | Veralox Therapeutics Business Decision. | 2025-11-17 |
| NCT05040776 Withdrawn | Withdrawn | Sponsor decision | 2025-05-31 |
| NCT04861181 Terminated | Terminated | End of inclusion period. | 2025-04-17 |
| NCT03891576 Terminated | Terminated | Low accrual rate | 2024-08-31 |
| NCT04931849 Withdrawn | Withdrawn | PI and Sponsor decided to not proceed with the trial. | 2024-07-18 |
| NCT03059030 Terminated | Terminated | Low enrollment | 2024-04-04 |
| NCT05091684 Terminated | Terminated | Only one patient was included in this study due to overly restrictive inclusion and exclusion criteria. | 2023-06-27 |
| NCT04889326 Withdrawn | Withdrawn | COVID | 2023-05-01 |
Trial records
Individual study records live on ClinicalTrials.gov. A sample of the trials counted above: